A Clinical Study of Immunotherapy Combined With Chemotherapy and Anti-angiogenic Therapy in Operable NSCLC

NCT05360979 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

42

Enrollment

OTHER

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: envafolimab

Sponsor

Second Xiangya Hospital of Central South University